Treatment of long-bone pseudarthrosis using a plasmid construct encoding VEGF and BMP-2: a pilot study
N.N. Priorov Journal of Traumatology and Orthopedics · 20.02.2026 · 33 (2) · 305-315
DOI: 10.17816/vto678750 ↗Kurz gefasst
Fachartikel in der Zeitschrift N.N. Priorov Journal of Traumatology and Orthopedics, online erschienen am 20.02.2026. Verfasst von Ramil Z. Salikhov und 6 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Pseudarthrosis of long bones following fractures represents a significant challenge in modern traumatology and orthopedics due to pronounced functional impairment of the affected limb and prolonged treatment duration. Novel approaches in regenerative medicine and orthobiologics provide promising opportunities to correct osteogenic insufficiency in the nonunion site, particularly after repeated surgical interventions. AIM: The work aimed to evaluate the prospects for clinical application of bone grafts containing genes encoding vascular endothelial growth factor (VEGF) and bone morphogenetic protein-2 (BMP-2) delivered via a plasmid construct for the treatment of patients with pseudarthrosis. METHODS: The plasmid construct pBudKan-coVEGF165A-coBMP2 was generated using standard molecular genetic techniques. Gene-activated demineralized bone allografts were produced by combining demineralized bone allografts with the plasmid construct. A single-center, prospective, uncontrolled cohort study included evaluation of experimental surgical treatment in 47 patients with long-bone pseudarthrosis who underwent bone grafting with the prepared grafts using either plate osteosynthesis or an external fixation device. Radiographic methods and the Non-Union Scoring System (NUSS) score were used to determine treatment strategy. Postoperative outcomes were evaluated by clinical examination, radiographic methods, and the Regenerating Bone defects using New biomedical Engineering (REBORNE) score. RESULTS: Treatment outcomes were monitored for 12 months in 46 patients. Positive treatment results were achieved in 95.7% of cases: 41 patients (89.1%) demonstrated complete bone union (REBORNE score = 4) after 6 months, and 3 patients (6.5%) after 12 months. CONCLUSION: The use of gene-activated demineralized bone allografts containing a plasmid construct simultaneously encoding VEGF and BMP-2 for bone grafting in patients with long-standing ununited fractures and prior unsuccessful treatment attempts resulted in a high rate of successful bone union (95.7%).
Zitieren
APA
Salikhov, R. Z., Teplov, O. V., Chekunov, M. A., Zhuravleva, M. N., Mukhamedshina, Y. O., Pankov, I. O., & Rizvanov, A. A. (2026). Treatment of long-bone pseudarthrosis using a plasmid construct encoding VEGF and BMP-2: a pilot study. N.N. Priorov Journal of Traumatology and Orthopedics, 33(2), 305-315. https://doi.org/10.17816/vto678750
Vancouver
Salikhov RZ, Teplov OV, Chekunov MA, Zhuravleva MN, Mukhamedshina YO, Pankov IO, et al. Treatment of long-bone pseudarthrosis using a plasmid construct encoding VEGF and BMP-2: a pilot study. N.N. Priorov Journal of Traumatology and Orthopedics. 2026;33(2):305-315. doi:10.17816/vto678750
BibTeX
@article{Salikhov2026,
author = {Salikhov, Ramil Z. and Teplov, Oleg V. and Chekunov, Mikhail A. and Zhuravleva, Margarita N. and Mukhamedshina, Yana O. and Pankov, Igor O. and Rizvanov, Albert A.},
title = {Treatment of long-bone pseudarthrosis using a plasmid construct encoding VEGF and BMP-2: a pilot study},
journal = {N.N. Priorov Journal of Traumatology and Orthopedics},
year = {2026},
volume = {33},
number = {2},
pages = {305--315},
doi = {10.17816/vto678750}
}
EUVIMED